Varenicline

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DRUG-VARENICLINE`
Type	Drug
Aliases	ChampixChantixВаренікліні
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Drug Facts

Class	α4β2 nicotinic acetylcholine receptor partial agonist
Mechanism	Selective partial agonist at the α4β2 nicotinic acetylcholine receptor — the principal mediator of nicotine-induced dopaminergic reward. Partial agonism produces modest dopamine release (relieving craving and withdrawal) while simultaneously blocking nicotine binding (reducing reinforcement from any cigarettes smoked during titration). Most effective monotherapy for tobacco cessation (USPSTF / AHCPR).
Typical dosing	PO: 0.5 mg once daily × days 1-3, then 0.5 mg BID × days 4-7, then 1 mg BID for weeks 2-12 (standard 12-week course). Set quit date for ~day 8. May extend additional 12 weeks if abstinent at week 12. Renal: CrCl <30 → max 0.5 mg BID; ESRD/dialysis → 0.5 mg daily.
Ukraine registered	True
NSZU reimbursed	False
Ukraine last verified	2026-05-18

Warnings

Neuropsychiatric symptoms — depression, agitation, hostility, suicidal ideation/behavior (removed from labeling 2016 after EAGLES trial but historical caution remains; counsel patients to report mood changes)

Notes

STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. Most effective single-agent for tobacco cessation (USPSTF + AHCPR). Combination with NRT may further improve quit rates but increases nausea. EAGLES trial (2016) reassured cardiovascular and neuropsychiatric safety vs placebo. Source cited (SRC-NCCN-BCELL-2025) is closest in-KB until USPSTF/AHCPR/Cochrane tobacco-cessation sources are added in a separate source-stub workstream.

Varenicline

Drug Facts

Warnings

Notes

Used By

Contraindications

Regimens